S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
Log in
NASDAQ:EDIT

Editas Medicine Price Target, Predictions & Analyst Ratings

$72.11
-4.03 (-5.29 %)
(As of 01/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$69.67
Now: $72.11
$76.90
50-Day Range
$31.56
MA: $68.03
$90.58
52-Week Range
$14.01
Now: $72.11
$99.95
Volume3.56 million shs
Average Volume3.08 million shs
Market Capitalization$4.49 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.1

Analyst Ratings

Editas Medicine (NASDAQ:EDIT) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Editas Medicine in the last 12 months. Their average twelve-month price target is $50.83, predicting that the stock has a possible downside of 29.51%. The high price target for EDIT is $86.00 and the low price target for EDIT is $14.00. There are currently 2 sell ratings, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
EDIT Consensus Rating: HoldHoldHoldHold
EDIT Consensus Rating Score: 2.132.382.432.43
EDIT Analyst Ratings: 2 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
EDIT Consensus Price Target: $50.83$51.17$44.80$39.20
EDIT Price Target Upside: 29.51% downside31.26% upside47.14% upside50.42% upside

Editas Medicine (NASDAQ:EDIT) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Editas Medicine (NASDAQ:EDIT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/20/2021JPMorgan Chase & Co.Reiterated RatingHoldN/A
1/19/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$64.00 ➝ $45.00Low
1/13/2021Wells Fargo & CompanyBoost Price TargetOverweight$69.00 ➝ $86.00Medium
1/7/2021Raymond JamesDowngradeOutperform ➝ Market PerformN/A
11/2/2020Robert W. BairdInitiated CoverageUnderperform$14.00High
6/18/2020SunTrust BanksInitiated CoverageBuy$45.00High
6/15/2020OppenheimerReiterated RatingHoldHigh
6/12/2020Chardan CapitalReiterated RatingBuy$55.00High
4/11/2019Evercore ISIInitiated CoverageOutperformMedium
2/7/2019BTIG ResearchInitiated CoverageBuy$30.00Low
1/22/2019CowenReiterated RatingBuyMedium
10/9/2018GuggenheimInitiated CoverageNeutral ➝ NeutralHigh
3/7/2018BarclaysBoost Price TargetOverweight ➝ Overweight$28.00 ➝ $46.00Medium
3/7/2018JMP SecuritiesBoost Price TargetOutperform$40.00 ➝ $67.00High
2/13/2018CLSAInitiated CoverageUnderperform ➝ UnderperformLow
(Data available from 1/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.